NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

27940.00 420.00 (1.53%)

52W Low on Apr 24, 2026

20,044 NSE+BSE Volume

NSE 15 May, 2026 3:31 PM (IST)

59,370.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Target Downgrade

BOB Capital Markets retains its 'Buy' call on Abbott, with a lower target price of Rs 36,457 See details

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

13 May 2026

27940.00

1.53%

Abbott India (BUY): In line earnings; EBITDA Margin likely to sustain near its highs

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported -0.4%, -1.7%, -2.1% below our estimates. EBITDA Margin reported at 40 bps below our estimates

BOB Capital Markets Ltd. decreased Buy price target of Abbott India Ltd. to 36457.0 on 13 May, 2026.

Abbott India Ltd.

12 May 2026

27940.00

1.53%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Direct

The company also markets some leading brands of Novo Nordisk and Abbott Healthcare for which it receives distribution margins. Some of the leading distributed brands- Human Mixtard, Ryzodeg, Novomix and...

BOB Capital Markets Ltd. decreased Buy price target of Abbott India Ltd. to 36457.0 on 13 May, 2026.

Abbott India Ltd.

13 Feb 2026

27940.00

1.53%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Direct

New introduction tempo also maintained- Overall growth continues to be driven by legacy power brands (top 10 brands CAGR ~10% between January 23-26 despite slowdown in Mixtard and Novomix) and traction in few brands from the marketed portfolio. The company remains a standout performer among MNCs on the back of new products launch trajectory (+100 launches in the last 12 years and another 75 planned for the next 5 years) and performance consistency in most of the legacy brands. In FY25, the company introduced 7 new brands- Citrosoda UTI, Digene Insta,...

Abbott India Ltd. is trading above its 150 day SMA of 27763.1

Abbott India Ltd.

27 Nov 2025

27940.00

1.53%

Abbott India (BUY): Visibility of margin improvement

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Mixtard 50 injectables off the shelf from Aug'25, yet monthly sales were Rs705 mn inAug'25, 762 mn in Sep'25 and Rs 710 mn in Oct'25

Abbott India Ltd. is trading above its 150 day SMA of 27763.1

Abbott India Ltd.

09 Nov 2025

27940.00

1.53%

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd. is trading above its 150 day SMA of 27763.1

Abbott India Ltd.

08 Nov 2025

27940.00

1.53%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...

Abbott India Ltd. is trading above its 150 day SMA of 27763.1

Abbott India Ltd.

07 Nov 2025

27940.00

1.53%

Abbott India (BUY): Robust profitability amid GLP1 wave

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales reported 1.3% below while EBITDA/PAT reported 4.5%/6.4% above our estimates. EBITDA margin was 160 bps higher estimates

Abbott India Ltd. is trading below its 200 day SMA of 28817.0

Abbott India Ltd.

17 Sep 2025, 12:00AM

27940.00

1.53%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.